Business
STAAR Surgical Announces the EVO Implantable Lens US Clinical Trial is Underway with 1st Patient Implanted at Price Vision Group in Indianapolis on January 30th
LAKE FOREST, Calif. & INDIANAPOLIS--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable
About this update from Staar Surgical Company
[{"type":"text","content":" LAKE FOREST, Calif. & INDIANAPOLIS--(BUSINESS WIRE)--\nSTAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first patient was implanted in the Company’s U.S. human clinical study for its EVO ICL family of lenses. The investigational study, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens,” will be conducted at more than a dozen ophthalmology clinics across the United States. EVO Visian ICLs are intended to treat a wide range of refractive error, including myopia (nearsightedness) which is the need for distance vision correction. Myopia is the most common ocular disorder worldwide and its incidence is increasing rapidly. An estimated 1.9 billion people globally have myopia and this number is projected to rise by 52% by the year 2050.1 \nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005306/en/If you suffer from nearsightedness or astigmatism, the EVO Investigational lens is designed to improve your distance vision without glasses or contact lenses. (Photo: Business Wire)\n\n“Enrolling and implanting patients in the U.S. trial of our EVO family of implantable Collamer lenses is the next step in opening the U.S. market, the second largest market in the world for refractive vision correction, to our latest generation of lenses,” said Caren Mason, President & CEO of STAAR Surgical. “Surgeons outside the U.S. have implanted in excess of 750,000 of our EVO lenses in patients as the need for distance vision correction grows. We look forward to the U.S. study of our EVO lenses generating additional safety data on our implantable Collamer lenses.”\n\n\nOphthalmology clinics participating in the study include locations in the following metropolitan areas: Indianapolis, Chicago, Dallas, Washington D.C., Philadelphia, St. Louis, San Antonio, Kansas City, Cleveland, Honolulu, Omaha, Fargo and Salt Lake City.\n\n\nThe first patient in the U.S. clinical study of EVO implantable lenses was enrolled at Price Vision Group in Indianapolis. Francis W. Price, Jr. MD, study investigator and founder of Price Vision Group and the Cornea Research Foundation of America, stated, “My team and I very much enjoy investigating new and next...